Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34764962/
Graft versus host disease (GvHD) is a life-threating complication of allogeneic hematopoietic stem cell transplantation, which is initially treated with high dose corticosteroids. Approximately 50% of acute GvHD cases are resistant to steroid treatment, and two-year mortality rates in those steroid- ...
It is well-established that extensive culture expansion of primary donor-derived MSCs leads to marked changes in functionality, and that there is a high level of inter-donor variability in MSC properties. However, recent manufacturing innovations may be capable of overcoming these problems. Further adequately powered prospective studies are required to confirm efficacy and establish the place of MSC therapy in the treatment of this condition.
• Source: Frontiers in Immunology
• Conclusion/Relevance: “The subject of this review is the use of mesenchymal stromal cells (MSCs) in the context of GvHD. Over the past two decades, there has been extensive interest in the potential therapeutic use of MSCs in a wide range of clinical settings, including in support of HSCT and in the treatment of GvHD.”
• To date interest in the use of MSCs to treat acute GVHD has been greater than the interest in treating chronic GVHD, although the latter condition warrants attention, too, per the authors.
• In addition to immunomodulation, MSCs can limit tissue damage and trigger tissue repair secondary to paracrine effects on other endogenous recipient cells
• Recent advances could help surmount problems secondary to inter-donor variability and functional changes associated with extensive culture expansion. Adequately powered prospective studies are needed to support the efficacy of MSC therapy, as well as its place in treatment regimens for GVHD.